• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺低分化癌。一种针对高危乳头状和滤泡状癌患者群体的临床病理实体。

Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.

作者信息

Sakamoto A, Kasai N, Sugano H

出版信息

Cancer. 1983 Nov 15;52(10):1849-55. doi: 10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x.

DOI:10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x
PMID:6313176
Abstract

The relationship between histologic type and survival of 258 thyroid malignancies has been analysed. A new clinicopathologic entity, poorly differentiated carcinoma of the thyroid, is proposed. Papillary and follicular carcinomas of the thyroid showed no significant difference in survival rates. Both tumors were histologically separated into well differentiated and poorly differentiated carcinomas, so that thyroid cancer, deriving from follicular cells, was divided into well differentiated, poorly differentiated, and anaplastic carcinomas. The characteristic histology of poorly differentiated carcinoma was the presence of solid, trabecular and/or scirrhous patterns. Poorly differentiated carcinoma was found in 13.6% of all thyroid malignancies, and its prognosis was worse than that of well differentiated carcinoma. The differences of survival rates among well differentiated, poorly differentiated and anaplastic carcinomas were statistically significant. Prognostic data support the suggestion that the clinicopathologic entity of poorly differentiated carcinoma is of value in determining management and survival of thyroid cancer patients.

摘要

分析了258例甲状腺恶性肿瘤的组织学类型与生存率之间的关系。提出了一种新的临床病理实体——甲状腺低分化癌。甲状腺乳头状癌和滤泡状癌的生存率无显著差异。这两种肿瘤在组织学上均分为高分化和低分化癌,因此起源于滤泡细胞的甲状腺癌分为高分化、低分化和未分化癌。低分化癌的特征性组织学表现为实性、小梁状和/或硬癌模式。低分化癌占所有甲状腺恶性肿瘤的13.6%,其预后比高分化癌差。高分化、低分化和未分化癌之间的生存率差异具有统计学意义。预后数据支持以下观点:低分化癌的临床病理实体在确定甲状腺癌患者的治疗和生存方面具有价值。

相似文献

1
Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.甲状腺低分化癌。一种针对高危乳头状和滤泡状癌患者群体的临床病理实体。
Cancer. 1983 Nov 15;52(10):1849-55. doi: 10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x.
2
Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.具有小梁状、岛状和实性结构的甲状腺低分化癌:183例患者的临床病理研究
Cancer. 2004 Mar 1;100(5):950-7. doi: 10.1002/cncr.20087.
3
Multivariate study of prognostic factors for differentiated thyroid carcinoma: the significance of histologic subtype.分化型甲状腺癌预后因素的多变量研究:组织学亚型的意义
Int Surg. 1993 Jan-Mar;78(1):10-5.
4
Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?未分化甲状腺癌:需要分化到何种程度?
Am J Surg Pathol. 2011 Dec;35(12):1866-72. doi: 10.1097/PAS.0b013e31822cf962.
5
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories.p27KIP1 的下调以及 Ki67/Mib1 标记指数支持将甲状腺癌分类为具有预后相关性的类别。
Am J Surg Pathol. 1999 Jun;23(6):678-85. doi: 10.1097/00000478-199906000-00007.
6
Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas.致命性非间变性滤泡细胞源性甲状腺癌的临床病理特征
Thyroid. 2016 Nov;26(11):1588-1597. doi: 10.1089/thy.2016.0247. Epub 2016 Sep 7.
7
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.甲状腺肿瘤中的BRAF突变仅限于乳头状癌以及由乳头状癌发展而来的间变性癌或低分化癌。
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404. doi: 10.1210/jc.2003-030838.
8
Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation.乳头状、低分化和间变性甲状腺癌中出现钉突样模式的流行:高级别转化的一种可能表现。
Am J Surg Pathol. 2015 Feb;39(2):260-5. doi: 10.1097/PAS.0000000000000329.
9
The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.生存素在甲状腺肿瘤中的作用:在高分化、低分化和未分化甲状腺癌中的表达差异
Thyroid. 2014 Mar;24(3):511-9. doi: 10.1089/thy.2013.0196. Epub 2013 Dec 13.
10
Histological and functional correlation of thyroid carcinoma by immunohistochemistry.
Indian J Pathol Microbiol. 1990 Jan;33(1):35-40.

引用本文的文献

1
The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.日本内分泌外科学会2024年修订的甲状腺肿瘤管理临床指南。
Endocr J. 2025 May 7;72(5):545-635. doi: 10.1507/endocrj.EJ24-0644. Epub 2025 Mar 8.
2
Aggressive Types of Malignant Thyroid Neoplasms.侵袭性恶性甲状腺肿瘤类型
J Clin Med. 2024 Oct 14;13(20):6119. doi: 10.3390/jcm13206119.
3
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.低分化甲状腺癌的预后:系统评价和荟萃分析。
Endocrinol Metab (Seoul). 2024 Aug;39(4):590-602. doi: 10.3803/EnM.2024.1927. Epub 2024 Jun 27.
4
A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.分化型甲状腺癌新实体的全面综述及深入见解。
Curr Oncol. 2024 Jun 9;31(6):3311-3328. doi: 10.3390/curroncol31060252.
5
Poorly differentiated thyroid carcinoma arising from substernal goiter: a case report.起源于胸骨后甲状腺肿的低分化甲状腺癌:一例报告
Ann Med Surg (Lond). 2024 Mar 18;86(5):3020-3024. doi: 10.1097/MS9.0000000000001868. eCollection 2024 May.
6
Demographic, clinical, and surgical features of patients undergoing thyroidectomy due to thyroid lesions in Southern Iran: A cross-sectional study.伊朗南部因甲状腺病变接受甲状腺切除术患者的人口统计学、临床和手术特征:一项横断面研究。
Health Sci Rep. 2024 Apr 1;7(4):e2012. doi: 10.1002/hsr2.2012. eCollection 2024 Apr.
7
Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.未分化甲状腺癌与间变性甲状腺癌的对比研究:真实世界的病理分布、死因归因和预后因素评估。
Front Endocrinol (Lausanne). 2024 Mar 13;15:1347362. doi: 10.3389/fendo.2024.1347362. eCollection 2024.
8
Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.低分化甲状腺癌的现有证据:用于临床决策的系统评价和亚组荟萃分析。
Endocrine. 2024 Aug;85(2):509-519. doi: 10.1007/s12020-024-03771-x. Epub 2024 Mar 19.
9
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.利用分子靶向药物和免疫检查点抑制剂治疗晚期甲状腺癌以实现甲状腺癌再分化。
Am J Cancer Res. 2024 Feb 15;14(2):407-428. doi: 10.62347/EJAA3388. eCollection 2024.
10
Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.未分化甲状腺癌:概念争议与临床影响。
Virchows Arch. 2024 May;484(5):733-742. doi: 10.1007/s00428-024-03752-5. Epub 2024 Feb 24.